Dr. Joanne Imperial departed as Class I director at CapsoVision, Inc.
“On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective immediately.”
CapsoVision, Inc — fact timeline
Source-grounded facts extracted from CapsoVision, Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. David S. Shields was appointed as Class I director at CapsoVision, Inc.
“On July 1, 2026, the Board of Directors (the “Board”) of CapsoVision Inc. (the “Company”) appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board”
CapsoVision, Inc shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year at the 2026-06-11 meeting.
“Proposal #2 for the ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was approved.”
CapsoVision, Inc shareholders approved Election of Class I Directors at the 2026-06-11 meeting.
“Proposal #1 for the election (re-election) of the Class I Directors. The nominees listed below were re-elected at the Meeting to serve as Class I Directors of the Company until the Company's 2029 annual meeting of stockholders.”
CapsoVision, Inc reported the fiscal quarter ended March 31, 2026 results: revenue $2.8 million.
“and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights • Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025. • Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume”
CapsoVision, Inc reported the full year ended December 31, 2025 results: revenue $13.6 million.
“Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.”
CapsoVision, Inc reported the fourth quarter ended December 31, 2025 results: revenue $3.9 million.
“Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024.”
CapsoVision, Inc reported preliminary financial results for fourth quarter and full year ended December 31, 2025.
“On March 20, 2026, the Company issued a press release announcing certain of its preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.”
CapsoVision, Inc issued 2,867,089 shares of common stock to selected accredited investors for $4.883 per Share.
“to the Investors in the Private Placement an aggregate of 2,867,089 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at $4.883 per Share, which represents a 5% discount to the March 16th closing price, as per the terms of the agreement. The Securities Purchase Agreement contains customary representations”
CapsoVision, Inc entered into Registration Rights Agreement with the Investors (effective 2026-03-16).
“In connection with the Private Placement, the Company entered into a registration rights agreement, dated March 16, 2026 (the “Registration Rights Agreement”), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably practicable following the filing thereof with the SEC.”
CapsoVision, Inc entered into Securities Purchase Agreement with selected accredited investors (the "Investors") valued at approximately $14 million (effective 2026-03-16).
“On March 16, 2026, CapsoVision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (the “Investors”), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the “Private Placement”).”
CapsoVision, Inc amended Amendment with Canon, Inc, a Japanese corporation valued at $1 million (effective 2026-03-09).
“On March 9, 2026, the Company entered into the amendment to the original development agreement (the “ Amendment”) with Canon, Inc, a Japanese corporation pursuan t to which the Company agreed that the total fee shall be increased by the amount of $1 million due to the increased features in the specification.”
CapsoVision, Inc: Amended and restated bylaws became effective July 3, 2025 in connection with IPO closing (effective 2025-07-03).
“On July 3, 2025, the Company filed its amended and restated certificate of incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware and its amended and restated bylaws (the “ Bylaws ”) became effective in connection with the closing of the Public Offering.”
CapsoVision, Inc: Amended and restated certificate of incorporation filed with Delaware Secretary of State effective July 3, 2025 in connection with IPO closing (effective 2025-07-03).
“On July 3, 2025, the Company filed its amended and restated certificate of incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware and its amended and restated bylaws (the “ Bylaws ”) became effective in connection with the closing of the Public Offering.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.